Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics in treatment of rheumatoid arthritis.

Current pharmaceutical design - 1 Jan 2010

Kooloos W M, Huizinga T W J, Guchelaar H-J, Wessels J A M

Abstract excerpt

Over the last decades important progress is being made regarding disease modifying anti-rheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis (RA). Nevertheless, a substantial part of the patients fail to achieve a good response and/or experience toxicity, which limits further treatment leading to progression of inflammation and destruction of joints. These high interindividual differences in drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Arthritis, Rheumatoid
Share to TNF gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 20205662
DOI: 10.2174/138161210790112764

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics in treatment of rheumatoid arthritis.PMID 20205662Read ↗

Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine.Semantic proximity Read ↗

Pharmacogenetics of therapies in rheumatoid arthritis: An update.Semantic proximity Read ↗

The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.Semantic proximity Read ↗

Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and PharmacogeneticsSemantic proximity Read ↗

Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis.Semantic proximity Read ↗

Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients.Semantic proximity Read ↗

Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.Semantic proximity Read ↗

Pharmacogenetics and pharmacogenomics in rheumatology.Semantic proximity Read ↗

Predicting response to TNF antagonists in rheumatoid arthritis: the promise of pharmacogenetics research using clinical registries.Semantic proximity Read ↗

Pharmacogenomics in rheumatoid arthritis.Semantic proximity Read ↗

Testing pharmacogenetic indices to predict efficacy and toxicity of methotrexate monotherapy in a rheumatoid arthritis patient cohort.Semantic proximity Read ↗

Pharmacogenetics of disease-modifying anti-rheumatic drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.